ClinicalTrials.gg
RecruitingNCT07311564Updated May 20, 2026

A Study of LAD603 in Adults With Alopecia Areata

A Phase 2 interventional study of LAD603 and Placebo in Alopecia Areata, sponsored by Almirall, S.A.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Almirall, S.A. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Planned enrollment
19th of 84
136 · median 46
Started
2025
with 10 others
Phase 2
42 of 98
8 open now
Primary completion
2027-06
later than 11 of 31 live
Registered
93rd of 98
by date

Among the 98 studies in Alopecia Areata with a site in United States, this one is the 19th largest by planned enrollment of the 84 interventional ones that give a count, is one of 11 that started in 2025, is one of 42 in phase 2, reaches primary completion later than 11 of the 31 other live ones, and was the 93rd registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.

03

Conditions studied

  • Alopecia Areata

Keywords

  • Hair Loss
  • Hypotrichosis
  • Alopecia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is a male or female between 18 and 65 years old at the time of signing the .
  • Severe to very severe AA criteria:

    1. Greater than or equal to (>=) 50% hair loss of the scalp as measured by SALT without evidence of terminal hair regrowth within 6 months at both the Screening and Baseline (Day 1) visits.
    2. Current episode of hair loss lasting at least 6 months and not exceeding 7 years.
  • Participants who are or male must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD603 during the study,

Exclusion criteria

Exclusion Criteria:

AA, Skin Specific, and Other Inflammatory Diseases

  • Participants have other types of alopecia (including but not limited to traction, scarring alopecia).
  • Participants with "diffuse" type AA.
  • Currently has an active form of other inflammatory skin disease(s) or evidence of skin condition (e.g., psoriasis, seborrheic dermatitis, lupus) at the time of the Screening or Baseline (Day 1) visits that is expected to interfere with the assessment of alopecia areata severity.

Other Medical Conditions

  • Participant has previous severe adverse reaction to subcutaneously administered medication.
  • Participant has any of the following liver safety laboratory results at Screening

    1. (ALT) or aspartate aminotransferase (AST) greater than or equal to (>=) 2.5 × (ULN)
    2. Total (TBL) >=1.5 × ULN (TBL >=3 × ULN in participants with Gilbert's syndrome)
    3. Alkaline phosphatase (ALP) >=1.5 × ULN

      Prior/Concomitant Therapy

  • Intention to use any concomitant medication that is not permitted by this protocol or failure to undergo the required for a particular prohibited medication.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    LAD603 Dose A

    Participants will receive LAD603 Dose A , Subcutaneous (SC) injection from Day 1 up to 28 weeks.

    Drug: LAD603

  • Experimental
    LAD603 Dose B

    Participants will receive LAD603 Dose B, SC injection from Day 1 up to 28 weeks.

    Drug: LAD603

  • Experimental
    LAD603 Dose C

    Participants will receive LAD603 Dose C, SC injection from Day 1 up to 28 weeks.

    Drug: LAD603

  • Placebo comparator
    Placebo for LAD603

    Participants will receive Placebo for LAD603 SC injection from Day 1 up to 28 weeks.

    Other: Placebo

Interventions

  • DrugLAD603

    LAD603 administered subcutaneously.

  • OtherPlacebo

    LAD603 matching placebo administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in the Severity of Alopecia Tool (SALT) Score

    The SALT score is the sum of percentage of hair loss in all areas with a maximum score of 100 (higher score indicates greater hair loss).

    Time frame: Baseline, Week 28

Secondary outcomes

  1. Percentage of Participants Achieving an Absolute SALT Score Less than or Equal to (<=) 10/20

    Percentage of participants achieving an absolute SALT score of \<= 10/20. The SALT score is the sum of percentage of hair loss in all areas with a maximum score of 100 (higher score indicates greater hair loss). Total percentage of patients with absolute SALT score of \<= 10/20 will be calculated.

    Time frame: At Week 28

  2. Percentage of Participants Achieving a Clinician-Reported Outcome (ClinRO) for Eyelash Hair Loss of 0/1

    The ClinROs for Eyelash Hair Loss is a clinician reported assessment which measures the severity and impact of hair loss in these specific areas. It comprises a 4-point category response options (0 to 3) rating the extent of eyebrow hair loss. This scale ranges from no hair loss (0) to complete hair loss (3).

    Time frame: At Week 28

  3. Percentage of Participants Achieving a ClinRO for Eyebrow Hair Loss of 0/1

    The ClinROs for Eyebrow Hair is a clinician reported assessment which measures the severity and impact of hair loss in these specific areas. It comprises a 4-point category response options (0 to 3) rating the extent of eyebrow hair loss. This scale ranges from no hair loss (0) to complete hair loss (3).

    Time frame: At Week 28

07

Study locations

1 of 1 sites recruiting
  • Investigator Site 1
    Omaha, Nebraska 68144, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2025
First posted
Dec 31, 2025
StartActual
Dec 17, 2025
Primary completionEst.
Jun 23, 2027
CompletionEst.
Nov 21, 2027
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07311564
Lead sponsor
Almirall, S.A.
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Dec 17, 2025
Primary completion
Jun 23, 2027 (estimated)
Completion
Nov 21, 2027 (estimated)
Last update
May 20, 2026

Study contacts

Davide Carluccio
Contact
gco@almirall.com
Estrella García
Contact
gco@almirall.com
Study Director
study director · Almirall, S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion